Singapore markets closed
Straits Times Index
3,313.48 +8.49 (+0.26%) Nikkei
38,787.38 -132.88 (-0.34%) Hang Seng
19,553.61 +177.08 (+0.91%) FTSE 100
8,420.26 -18.39 (-0.22%) Bitcoin USD
66,943.06 +1,812.11 (+2.78%) CMC Crypto 200
1,364.81 -9.04 (-0.66%)
Can-Fite BioPharma Ltd. (CANF)
NYSE American - Nasdaq Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
Currency in USD
Valuation measures4
| Market cap (intra-day) | 10.60M |
| Enterprise value | 1.72M |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG ratio (5-yr expected) | N/A |
| Price/sales (ttm) | 12.83 |
| Price/book (mrq) | 1.79 |
| Enterprise value/revenue | 2.31 |
| Enterprise value/EBITDA | 0.22 |
Trading information
Stock price history
| Beta (5Y monthly) | 0.91 |
| 52-week change 3 | -3.03% |
| S&P500 52-week change 3 | 26.36% |
| 52-week high 3 | 3.3300 |
| 52-week low 3 | 1.8100 |
| 50-day moving average 3 | 2.1426 |
| 200-day moving average 3 | 2.2457 |
Share statistics
| Avg vol (3-month) 3 | 19.93k |
| Avg vol (10-day) 3 | 26.01k |
| Shares outstanding 5 | 4.99M |
| Implied shares outstanding 6 | 4.08M |
| Float 8 | 1.38B |
| % held by insiders 1 | 0.00% |
| % held by institutions 1 | 9.57% |
| Shares short (30 Apr 2024) 4 | 9.93k |
| Short ratio (30 Apr 2024) 4 | 0.46 |
| Short % of float (30 Apr 2024) 4 | N/A |
| Short % of shares outstanding (30 Apr 2024) 4 | 0.18% |
| Shares short (prior month 28 Mar 2024) 4 | 7.46k |
Dividends & splits
| Forward annual dividend rate 4 | N/A |
| Forward annual dividend yield 4 | N/A |
| Trailing annual dividend rate 3 | 0.00 |
| Trailing annual dividend yield 3 | 0.00% |
| 5-year average dividend yield 4 | N/A |
| Payout ratio 4 | 0.00% |
| Dividend date 3 | 10 May 2019 |
| Ex-dividend date 4 | N/A |
| Last split factor 2 | 1:10 |
| Last split date 3 | 09 Jan 2023 |
Financial highlights
Fiscal year
| Fiscal year ends | 31 Dec 2023 |
| Most-recent quarter (mrq) | 31 Dec 2023 |
Profitability
| Profit margin | 0.00% |
| Operating margin (ttm) | -1,183.23% |
Management effectiveness
| Return on assets (ttm) | -53.15% |
| Return on equity (ttm) | -142.49% |
Income statement
| Revenue (ttm) | 743k |
| Revenue per share (ttm) | 0.30 |
| Quarterly revenue growth (yoy) | -21.30% |
| Gross profit (ttm) | N/A |
| EBITDA | -8.18M |
| Net income avi to common (ttm) | -7.63M |
| Diluted EPS (ttm) | -3.0000 |
| Quarterly earnings growth (yoy) | N/A |
Balance sheet
| Total cash (mrq) | 8.92M |
| Total cash per share (mrq) | 0.01 |
| Total debt (mrq) | 40k |
| Total debt/equity (mrq) | 0.64% |
| Current ratio (mrq) | 4.91 |
| Book value per share (mrq) | 0.00 |
Cash flow statement
| Operating cash flow (ttm) | -8.44M |
| Levered free cash flow (ttm) | -5.12M |
© 2024 Yahoo. All rights reserved.